British_NP Cancer_NP Research_NP Meeting_NP ,_, 30_CD June-3_NP July_NP 2002_CD ,_, Glasgow_NP Abstract_NP |_SYM The_DT 2002_CD British_NP Cancer_NP Research_NP Meeting_NP was_VBD held_VBN from_IN 30th_JJ June_NP to_TO 3rd_JJ July_NP in_IN Glasgow_NP ,_, UK_NP ._SENT The_DT meeting_NN was_VBD structured_VBN to_TO include_VB educational_JJ workshops_NNS ,_, plenary_JJ lectures_NNS ,_, symposia_NNS ,_, and_CC poster_NN sessions_NNS ,_, which_WDT brought_VBD together_RB scientists_NNS and_CC clinicians_NNS ._SENT Presentations_NNS ranged_VBD from_IN the_DT impact_NN that_IN modifications_NNS to_TO basic_JJ chromatin_NN structure_NN can_MD have_VB on_IN diagnosis_NN and_CC targeted_JJ gene_NN therapy_NN ,_, to_TO the_DT outcome_NN of_IN novel_JJ therapeutics_NNS through_IN clinical_JJ trials_NNS ._SENT The_DT emphasis_NN was_VBD clear_JJ :_: patient_NN survival_NN is_VBZ the_DT main_JJ priority_NN and_CC treatment_NN of_IN organ-specific_JJ cancer_NN must_MD inevitably_RB be_VB replaced_VBN by_IN individualised_VBN tumour-specific_JJ therapy_NN ._SENT chromatin_NN remodelling_NN ,_, microarrays_NNS ,_, targeted_JJ therapy_NN ,_, Rain_NP and_CC the_DT city_NN of_IN Glasgow_NP are_VBP almost_RB synonymous_JJ and_CC sadly_RB this_DT was_VBD indeed_RB the_DT case_NN for_IN the_DT duration_NN of_IN the_DT British_NP Cancer_NP Research_NP Meeting_NP 2002_CD ,_, held_VBN at_IN the_DT Scottish_NP Exhibition_NP and_CC Conference_NP Centre_NP from_IN 30th_JJ June_NP to_TO 3rd_JJ July_NP ._SENT The_DT rain_NN did_VBD not_RB dampen_VB the_DT spirits_NNS of_IN the_DT almost_RB 600_CD delegates_NNS ,_, however_RB ,_, and_CC a_DT feast_NN of_IN good_JJ science_NN was_VBD enjoyed_VBN ._SENT This_DT ranged_VBD from_IN plenary_JJ sessions_NNS and_CC award_NN lectures_VBZ to_TO proffered_VBN paper_NN sessions_NNS and_CC posters_NNS ,_, covering_VBG various_JJ aspects_NNS of_IN clinically_RB diagnosed_VBN and_CC experimental_JJ cancer_NN models_NNS ._SENT Here_RB we_PP present_VB some_DT of_IN the_DT highlights_NNS ._SENT A_DT number_NN of_IN scientists_NNS ,_, both_CC young_JJ and_CC established_JJ ,_, were_VBD honoured_VBN at_IN the_DT meeting_NN for_IN their_PP$ contributions_NNS to_TO cancer_NN research_NN ._SENT The_DT British_NP Association_NP for_IN Cancer_NP Research_NP (_( BACR_NP )_) Tom_NP Connors_NP Award_NP Lecture_NP "_'' Close_NP Encounters_NP of_IN a_DT Molecular_NP Kind_NP "_'' was_VBD given_VBN by_IN Malcolm_NP Stevens_NP (_( University_NP of_IN Nottingham_NP ,_, UK_NP )_) ._SENT In_IN his_PP$ lecture_NN ,_, he_PP outlined_VBD the_DT need_NN to_TO nurture_NN '_POS cunning_NN '_'' rather_RB than_IN '_'' stunning_JJ '_'' chemistry_NN as_IN the_DT way_NN forward_RB in_IN drug_NN discovery_NN ._SENT The_DT BACR_NP Translational_NP Research_NP Award_NP went_VBD to_TO his_PP$ colleague_NN Tracey_NP Bradshaw_NP for_IN her_PP$ work_NN on_IN Phortress_NP ._SENT In_IN an_DT eloquent_JJ presentation_NN ,_, the_DT history_NN of_IN Phortress_NP was_VBD outlined_VBN ,_, underlining_VBG the_DT interplay_NN between_IN chemistry_NN and_CC biology_NN that_WDT led_VBD to_TO its_PP$ development_NN and_CC selection_NN as_IN a_DT candidate_NN therapy_NN ._SENT Phortress_NP evolved_VBD from_IN polyhydroxylated_JJ 2-phenylbenzothiazoles_NNS designed_VBN as_IN potential_JJ tyrosine_NN kinase_NN inhibitors_NNS ._SENT In_IN laboratory_NN studies_NNS it_PP has_VBZ shown_VBN very_RB promising_JJ results_NNS in_IN treating_VBG breast_NN and_CC ovarian_JJ cancers_NNS and_CC it_PP will_MD shortly_RB be_VB undergoing_VBG Phase_NP I_NP clinical_JJ trials_NNS ._SENT Marie_NP Boyd_NP (_( University_NP of_IN Glasgow_NP ,_, UK_NP )_) received_VBD the_DT BACR_NP Young_NP Scientist_NP Award_NP and_CC outlined_VBD the_DT exciting_JJ prospect_NN of_IN linking_VBG conventional_JJ radiation-based_JJ therapies_NNS with_IN gene_NN therapy_NN for_IN treating_VBG malignancy_NN ._SENT In_IN "_`` Re-designing_NP Cancer_NP Therapy_NP "_'' ,_, Sir_NP David_NP Lane_NP (_( University_NP of_IN Dundee_NP ,_, UK_NP )_) emphasised_VBD the_DT need_NN for_IN patient-specific_JJ therapy_NN ,_, a_DT consensus_NN that_WDT was_VBD reiterated_VBN throughout_IN the_DT conference_NN ._SENT He_PP also_RB discussed_VBD the_DT necessity_NN of_IN looking_VBG not_RB only_RB at_IN the_DT gene_NN in_IN question_NN ,_, but_CC also_RB at_IN the_DT whole_JJ signalling_VBG pathway_NN in_IN which_WDT it_PP is_VBZ involved_VBN ._SENT We_PP were_VBD reminded_VBN that_IN 24_CD %_NN of_IN human_JJ breast_NN cancers_NNS have_VBP genetic_JJ changes_NNS in_IN the_DT p53_NN tumour_NN suppressor_NN gene_NN and_CC how_WRB p53_NN may_MD be_VB utilised_VBN as_IN a_DT target_NN for_IN gene_NN therapy_NN ._SENT The_DT role_NN of_IN p53_NN as_IN a_DT potential_JJ therapeutic_JJ target_NN was_VBD also_RB emphasised_VBN by_IN Barbara_NP Foster_NP (_( Pfizer_NP Global_NP R&D_NP ,_, Groton_NP ,_, CT_NP ,_, USA_NP )_) ._SENT Current_JJ strategies_NNS include_VBP the_DT pharmacological_JJ rescue_NN of_IN mutant_JJ p53_NN protein_NN ,_, using_VBG small_JJ chaperone_NN molecules_NNS ._SENT Both_DT speakers_NNS discussed_VBD various_JJ therapeutic_JJ strategies_NNS for_IN tumours_NNS that_WDT have_VBP mutations_NNS in_IN the_DT p53_NN gene_NN and_CC left_VBD us_PP with_IN the_DT notion_NN that_IN the_DT future_NN of_IN p53_NN as_IN a_DT therapeutic_JJ target_NN was_VBD very_RB much_RB alive_JJ ._SENT The_DT Cancer_NP Research_NP UK_NP Lecture_NP was_VBD given_VBN by_IN Olli_NP Kallioniemi_NP (_( National_NP Genome_NP Research_NP Institute_NP ,_, Bethesda_NP ,_, MD_NP ,_, USA_NP )_) ,_, who_WP discussed_VBD the_DT application_NN of_IN array_NN technology_NN in_IN cancer_NN research_NN ._SENT From_IN the_DT construction_NN of_IN simple_JJ RNA_NP or_CC DNA_NP arrays_NNS ,_, this_DT field_NN has_VBZ evolved_VBN rapidly_RB in_IN recent_JJ years_NNS ._SENT The_DT emerging_VBG challenge_NN now_RB is_VBZ to_TO uncover_VB the_DT function_NN of_IN the_DT many_JJ candidate_NN genes_NNS identified_VBN in_IN earlier_JJR genome_NN arrays_NNS by_IN integrating_VBG gene_NN copy_NN number_NN and_CC gene_NN expression_NN analysis_NN with_IN functional_JJ studies_NNS ._SENT The_DT development_NN of_IN tissue_NN microarrays_NNS ,_, in_IN which_WDT it_PP is_VBZ theoretically_RB possible_JJ to_TO represent_VB an_DT entire_JJ pathology_NN archive_NN on_IN a_DT single_JJ microscope_NN slide_NN (_( '_POS pathomics_NNS '_'' )_) ,_, is_VBZ one_CD way_NN forward_RB for_IN such_JJ high-throughput_NN analysis_NN ._SENT Tissue_NN microarrays_NNS allow_VBP population-level_JJ screening_NN and_CC cellular_JJ resolution_NN ,_, which_WDT are_VBP not_RB possible_JJ using_VBG genome_NN arrays_NNS ._SENT A_DT novel_NN slant_NN is_VBZ the_DT use_NN of_IN living_VBG gene_NN transfection_NN microarrays_NNS ._SENT With_IN this_DT technique_NN ,_, cultured_JJ cells_NNS are_VBP overlaid_VBN on_IN DNA_NN arrays_NNS ._SENT Those_DT cells_NNS that_WDT take_VBP up_RP DNA_NP create_VB spots_NNS of_IN localised_VBN transfection_NN ._SENT This_DT exciting_JJ new_JJ technology_NN has_VBZ applicability_NN for_IN identifying_VBG new_JJ drug_NN targets_NNS and_CC in_IN discovering_VBG gene_NN products_NNS which_WDT affect_VBP cell_NN physiology_NN ._SENT Another_DT innovative_JJ angle_NN involves_VBZ harnessing_VBG the_DT power_NN of_IN gene_NN transfection_NN microarrays_NNS with_IN RNA_NP interference_NN ._SENT RNA_NP interference_NN involves_VBZ the_DT processing_NN of_IN dsRNA_NN to_TO short_VB interfering_VBG RNA_NP of_IN about_RB 21_CD nucleotides_NNS ,_, as_IN a_DT form_NN of_IN post-transcriptional_JJ gene_NN silencing_VBG ._SENT This_DT is_VBZ often_RB manifested_VBN in_IN an_DT aberrant_JJ phenotype_NN ,_, which_WDT can_MD allow_VB gene_NN function_NN to_TO be_VB identified_VBN ._SENT Quite_RB literally_RB we_PP now_RB have_VBP available_JJ an_DT array_NN of_IN arrays_NNS and_CC ,_, bearing_VBG in_IN mind_NN how_WRB rapidly_RB this_DT field_NN continues_VBZ to_TO evolve_VB ,_, the_NP '_POS laboratory-on-a-chip_NN '_'' may_MD soon_RB be_VB here_RB ._SENT The_DT importance_NN of_IN histone_NN modification_NN and_CC chromatin_NN remodelling_NN is_VBZ becoming_VBG increasingly_RB recognised_VBN ,_, particularly_RB since_IN many_JJ important_JJ genes_NNS are_VBP methylated_VBN and_CC epigenetically_RB silenced_VBN in_IN tumours_NNS ._SENT In_IN a_DT whole_JJ session_NN dedicated_VBN to_TO this_DT subject_NN ,_, the_DT audience_NN was_VBD educated_VBN on_IN a_DT range_NN of_IN topics_NNS ,_, from_IN basic_JJ principles_NNS of_IN chromatin_NN structure_NN ,_, to_TO the_DT role_NN of_IN histone_NN modifying_VBG proteins_NNS and_CC methylation_NN in_IN chromatin_NN remodelling_NN ._SENT Histone_NN deacetylases_NNS and_CC DNA_NN methyl-transferase_NN inhibitors_NNS could_MD represent_VB new_JJ diagnostic_JJ or_CC therapeutic_JJ targets_NNS ._SENT Tony_NP Kouzarides_NP (_( Wellcome/Cancer_NP Research_NP UK_NP Institute_NP ,_, Cambridge_NP ,_, UK_NP )_) initiated_VBD this_DT session_NN in_IN the_DT BACR_NP Frank_NP Rose_NP Lecture_NP ,_, giving_VBG an_DT invigorating_VBG and_CC informative_JJ insight_NN into_IN the_DT role_NN of_IN "_`` Histone_NN Modifications_NNS in_IN Transcriptional_NP Control_NP "_'' ._SENT Particular_JJ emphasis_NN was_VBD given_VBN to_TO the_DT effect_NN of_IN gene_NN methylation_NN on_IN transcriptional_JJ repression_NN ,_, and_CC he_PP gave_VBD an_DT illustrative_JJ demonstration_NN of_IN the_DT downstream_JJ effects_NNS of_IN these_DT events_NNS ._SENT Interestingly_RB ,_, he_PP used_VBD the_DT estrogen_NN receptor_NN (ER)-regulated_JJ gene_NN pS2_NN as_IN a_DT model_NN to_TO demonstrate_VB the_DT complex_JJ sequence_NN of_IN events_NNS regulating_VBG gene_NN transcription_NN ._SENT The_DT focus_NN of_IN the_DT talk_NN was_VBD on_IN lysine_NN and_CC arginine_NN methylation_NN ._SENT Using_VBG chromatin_NN immunoprecipitations_NNS ,_, he_PP showed_VBD that_DT methylation_NN of_IN arginine_NN 17_CD on_IN the_DT histone_NN (_( H3_NP )_) tail_NN is_VBZ required_VBN for_IN activation_NN of_IN the_DT pS2_JJ gene_NN ._SENT The_DT order_NN of_IN events_NNS involves_VBZ recruitment_NN of_IN histone-modifying_VBG proteins_NNS ,_, acetylation_NN ,_, and_CC subsequent_JJ methylation_NN of_IN the_DT gene_NN before_IN its_PP$ activation_NN ._SENT The_DT presentation_NN was_VBD concluded_VBN with_IN the_DT possibility_NN of_IN using_VBG this_DT detailed_JJ information_NN on_IN pS2_NN to_TO produce_VB better_RBR defined_VBN targets_NNS for_IN therapy_NN and_CC molecular_JJ diagnosis_NN ._SENT Individual_JJ tumours_NNS have_VBP different_JJ patterns_NNS of_IN methylation_NN ,_, and_CC Robert_NP Brown_NP (_( University_NP of_IN Glasgow_NP ,_, UK_NP )_) also_RB emphasised_VBD the_DT potential_NN of_IN identifying_VBG gene_NN methylation_NN patterns_NNS in_IN specific_JJ tumours_NNS ._SENT Nick_NP La_NP Thangue_NP (_( University_NP of_IN Glasgow_NP ,_, UK_NP )_) highlighted_VBD the_DT use_NN of_IN histone_NN deacetylase_NN inhibitors_NNS as_IN cancer_NN therapeutics_NNS ._SENT One_CD candidate_NN ,_, PXD101_NP ,_, is_VBZ a_DT novel_JJ histone-deacetylase_NN antagonist_NN that_WDT blocks_VBZ tumour_NN growth_NN by_IN inducing_VBG apoptosis_NN and_CC has_VBZ little_JJ toxicity_NN in_IN mice_NNS ._SENT Advances_NNS in_IN cancer_NN therapeutics_NNS are_VBP continually_RB ongoing_JJ ,_, and_CC novel_NN strategies_NNS using_VBG DNA_NP methyl-transferase_NN inhibitors_NNS and_CC histone-deacetylase_NN inhibitors_NNS are_VBP already_RB showing_VBG promise_NN in_IN clinical_JJ trials_NNS ._SENT New_JJ predictive_JJ markers_NNS for_IN breast_NN cancer_NN are_VBP always_RB being_VBG sought_VBN and_CC work_NN presented_VBN by_IN Ramsey_NP Cutress_NP (_( University_NP of_IN Southampton_NP ,_, UK_NP )_) showed_VBD that_IN BAG-1_NP ,_, a_DT multifunctional_JJ protein_NN with_IN targets_NNS including_VBG heat_NN shock_NN proteins_NNS and_CC some_DT nuclear_JJ hormone_NN receptors_NNS ,_, may_MD have_VB potential_JJ in_IN predicting_VBG response_NN to_TO hormonal_JJ therapy_NN ._SENT In_IN a_DT study_NN of_IN 138_CD breast_NN cancers_NNS ,_, nuclear_JJ expression_NN of_IN BAG-1_NP was_VBD associated_VBN with_IN improved_VBN survival_NN ._SENT BAG-1_NP interacts_VBZ directly_RB with_IN ER-alpha_NP and_CC -beta_NP ._SENT Brid_NP Ryan_NP (_( St_NP Vincent_NP 's_POS University_NP Hospital_NP ,_, Dublin_NP ,_, Eire_NP )_) showed_VBD that_IN survivin_NP ,_, an_DT inhibitor-of-apoptosis_NN protein_NN ,_, may_MD have_VB potential_JJ in_IN prognosis_NN ._SENT Survivin_NP is_VBZ overexpressed_VBN in_IN many_JJ tumours_NNS ,_, including_VBG breast_NN ,_, is_VBZ inversely_RB correlated_VBN with_IN expression_NN of_IN ER_NN and_CC progesterone_NN receptor_NN and_CC is_VBZ positively_RB correlated_VBN with_IN tumour_NN grade_NN ._SENT Current_JJ indicators_NNS of_IN response_NN to_TO breast_VB cancer_NN therapy_NN rely_VBP on_IN the_DT hormonal_JJ status_NN of_IN tumour_NN tissue_NN ._SENT Tumours_NNS responsive_JJ to_TO endocrine_JJ hormones_NNS are_VBP treated_VBN with_IN the_DT ER_JJ antagonist_NN tamoxifen_NN ._SENT The_DT therapeutic_JJ efficacy_NN of_IN tamoxifen_NP is_VBZ compromised_VBN by_IN its_PP$ agonistic_JJ activity_NN in_IN some_DT tissue_NN types_NNS ._SENT Mitch_NP Dowsett_NP (_( Royal_NP Marsden_NP NHS_NN Trust_NP ,_, London_NP ,_, UK_NP )_) highlighted_VBD that_IN ER-negative_JJ (ER-)/progesterone_NN receptor-positive_NN patients_NNS also_RB benefit_VBP from_IN hormonal_JJ therapy_NN and_CC suggested_VBD that_DT identification_NN of_IN progesterone_NN receptor_NN in_IN the_DT small_JJ subset_NN of_IN ER-_NP tumours_NNS (_( 25_CD %_NN )_) should_MD also_RB be_VB ascertained_VBN prior_RB to_TO selecting_VBG adjuvant_JJ therapy_NN ._SENT He_PP described_VBD the_DT reduced_VBN benefit_NN tamoxifen_NN might_MD have_VB on_IN patients_NNS that_WDT have_VBP ER+_NP and_CC HER-2+_NP tumours_NNS ._SENT Matti_NP Aapro_NP (_( Clinique_NP de_NP Genolier_NP ,_, Switzerland_NP )_) addressed_VBD a_DT number_NN of_IN consensus_NN guidelines_NNS for_IN adjuvant_JJ therapy_NN ,_, and_CC both_DT Aapro_NP and_CC Dowsett_NP summarised_VBD the_DT findings_NNS of_IN the_DT recent_JJ ATAC_NP trial_NN in_IN which_WDT the_DT aromatase_NN inhibitor_NN anastrozole_NN was_VBD found_VBN to_TO be_VB superior_JJ to_TO tamoxifen_NP or_CC a_DT combination_NN of_IN both_DT drugs_NNS in_IN treating_VBG postmenopausal_JJ women_NNS with_IN early_JJ breast_NN cancer_NN ._SENT Aapro_NP proposed_VBD the_DT use_NN of_IN adjuvant_JJ drugs_NNS such_JJ as_IN Paclitaxel_NP ,_, in_IN the_DT early_JJ treatment_NN of_IN breast_NN cancer_NN ,_, to_TO improve_VB patient_JJ survival_NN ._SENT He_PP concluded_VBD that_IN one_CD specific_JJ drug_NN treatment_NN will_MD not_RB prove_VB successful_JJ for_IN all_DT patients_NNS and_CC that_DT organ-specific_JJ cancer_NN treatment_NN will_MD soon_RB be_VB superseded_VBN by_IN tumour-specific_JJ therapy_NN ._SENT This_DT idea_NN was_VBD reinforced_VBN by_IN Dowsett_NP ,_, who_WP encouraged_VBD the_DT idea_NN that_IN tumours_NNS should_MD be_VB seen_VBN as_IN individual_JJ entities_NNS and_CC should_MD be_VB treated_VBN specifically_RB ._SENT Tumour_NN metastases_NNS and_CC drug_NN resistance_NN remains_VBZ a_DT burden_NN on_IN the_DT current_JJ treatment_NN of_IN breast_NN cancer_NN ._SENT Both_DT Graham_NP Roche-Nagle_NP (_( Beaumont_NP Hospital_NP ,_, Dublin_NP ,_, Eire_NP )_) and_CC Thomas_NP Barry_NP (_( Mater_NP Hospital_NP ,_, Dublin_NP ,_, Eire_NP )_) presented_VBD data_NNS illustrating_VBG the_DT role_NN that_IN cyclo-oxygenase-2_NN (_( COX-2_NP )_) may_MD play_VB in_IN these_DT events_NNS ._SENT Using_VBG selective_JJ COX-2_NP inhibition_NN Roche-Nagle_NP demonstrated_VBD a_DT significant_JJ reduction_NN in_IN the_DT number_NN of_IN tumour_NN metastases_NNS in_IN an_DT orthotopic_JJ murine_JJ model_NN of_IN breast_NN cancer_NN ._SENT Microvessel_NN density_NN and_CC levels_NNS of_IN serum_NN vascular_JJ endothelial-cell_NN growth_NN factor_NN were_VBD also_RB reduced_VBN by_IN COX-2_NP inhibition_NN ._SENT Drug_NN delivery_NN and_CC targeting_VBG are_VBP important_JJ aspects_NNS of_IN cancer_NN therapy_NN that_WDT were_VBD covered_VBN in_IN several_JJ presentations_NNS ._SENT The_DT story_NN of_IN 5-(aziridin-l-yl)-2,4-dinitrobenzamide_NN (_( CB1954_NP )_) was_VBD presented_VBN by_IN Richard_NP Knox_NP (_( Enact_NP Pharma_NP plc_NP ,_, Salisbury_NP ,_, UK_NP )_) ._SENT CB1954_NP ,_, developed_VBN in_IN the_DT 1950s_NNS ,_, is_VBZ a_DT proven_JJ success_NN in_IN eradicating_VBG rat_NN tumours_NNS ,_, but_CC unfortunately_RB the_DT same_JJ effect_NN was_VBD never_RB observed_VBN in_IN human_JJ cancers_NNS ._SENT This_DT is_VBZ due_JJ to_TO differences_NNS in_IN the_DT bioactivation_NN of_IN CB1954_NP in_IN rats_NNS versus_CC humans_NNS :_: the_DT human_JJ form_NN of_IN the_DT enzyme_NN DT-diaphorase_NP (_( NQ01_NP )_) is_VBZ much_RB less_RBR efficient_JJ at_IN metabolising_VBG CB1954_NP ,_, which_WDT accounts_VBZ for_IN its_PP$ lack_NN of_IN activity_NN against_IN human_JJ cancers_NNS ._SENT New_JJ research_NN has_VBZ identified_VBN an_DT enzyme_NN (_( NQ02_NP )_) in_IN some_DT human_JJ tumours_NNS ,_, although_IN not_RB those_DT of_IN the_DT breast_NN ._SENT NQ02_NP is_VBZ several-fold_NN more_RBR effective_JJ than_IN NQ01_NP at_IN metabolising_VBG CB1954_NP and_CC a_DT Phase_NP I_NP trial_NN is_VBZ about_RB to_TO begin_VB ,_, with_IN the_DT aim_NN of_IN establishing_VBG the_DT efficacy_NN of_IN NQ02_NP as_IN a_DT more_RBR active_JJ substrate_NN for_IN CB1954_NP ._SENT Ruth_NP Duncan_NP (_( University_NP of_IN Cardiff_NP ,_, UK_NP )_) presented_VBD an_DT overview_NN of_IN tumour-specific_JJ drug_NN delivery_NN using_VBG polymer_NN --_: anticancer_NN conjugates_VBZ ._SENT To_TO date_NN ,_, successful_JJ receptor-mediated_JJ targeting_VBG has_VBZ been_VBN limited_VBN to_TO the_DT asialoglycoprotein_NN receptor_NN in_IN hepatic_JJ carcinomas_NNS ,_, but_CC HER2/neu_NP ,_, present_JJ in_IN some_DT breast_NN cancers_NNS ,_, could_MD represent_VB a_DT new_JJ target_NN for_IN polymer-based_JJ drug_NN delivery_NN ._SENT Gerry_NP Potter_NP (_( De_NP Montfort_NP University_NP ,_, Leicester_NP ,_, UK_NP )_) described_VBD some_DT of_IN the_DT actions_NNS of_IN the_DT human_JJ cytochrome_NN P450_NP CYP1B1_NP ,_, the_DT overexpression_NN of_IN which_WDT has_VBZ been_VBN observed_VBN in_IN many_JJ tumours_NNS ,_, including_VBG breast_NN ._SENT Many_JJ cytochrome_NN P450_NN enzymes_NNS are_VBP known_VBN to_TO metabolise_VB a_DT variety_NN of_IN anticancer_NN drugs_NNS ;_: the_DT consequence_NN of_IN cytochrome_NN P450_NN metabolism_NN is_VBZ usually_RB detoxification_NN of_IN the_DT drug_NN ,_, although_IN bioactivation_NN occurs_VBZ in_IN some_DT cases_NNS ._SENT With_IN this_DT in_IN mind_NN he_PP proposed_VBD that_IN CYP1B1_NP be_VB reclassified_VBN as_IN a_DT tumour-suppressor_NN enzyme_NN ,_, through_IN natural_JJ prodrug_NN bioactivation_NN ._SENT He_PP presented_VBD data_NNS showing_VBG that_IN some_DT natural_JJ dietary_JJ agents_NNS ,_, such_JJ as_IN phytoestrogens_NNS and_CC resveratrol_NN ,_, are_VBP converted_VBN into_IN anticancer_NN agents_NNS by_IN CYP1B1_NP ._SENT As_IN with_IN most_JJS international_JJ conferences_NNS ,_, the_DT gathering_NN of_IN many_JJ researchers_NNS ,_, scientists_NNS and_CC clinicians_NNS results_NNS in_IN the_DT generation_NN of_IN novel_NN ideas_NNS and_CC extensive_JJ discussions_NNS ._SENT The_DT outcome_NN ,_, foremost_RB ,_, drives_NNS delegates_NNS forward_RB in_IN their_PP$ areas_NNS of_IN cancer_NN research_NN ._SENT As_IN the_DT ultimate_JJ focus_NN is_VBZ on_IN improving_VBG patient_JJ survival_NN using_VBG chemopreventative_JJ and_CC chemotherapeutic_JJ drugs_NNS ,_, we_PP are_VBP reminded_VBN of_IN the_DT demands_NNS of_IN the_DT patient_NN ._SENT Perhaps_RB the_DT most_RBS significant_JJ message_NN from_IN this_DT meeting_NN is_VBZ the_DT necessity_NN and_CC inevitable_JJ development_NN of_IN a_DT tumour-specific_JJ drug_NN that_WDT is_VBZ tailored_VBN to_TO each_DT patient_NN 's_POS gene_NN profile_NN ,_, thus_RB meeting_VBG their_PP$ individual_JJ requirements_NNS ._SENT This_DT is_VBZ keenly_RB awaited_VBN ._SENT Perhaps_RB the_DT results_NNS of_IN research_NN in_IN these_DT areas_NNS ,_, including_VBG interim_JJ results_NNS from_IN the_DT Phase_NP I_NP trials_NNS mentioned_VBN above_IN ,_, will_MD be_VB presented_VBN at_IN the_DT next_JJ meeting_NN ._SENT The_DT next_JJ British_NP Cancer_NP Research_NP Meeting_NP will_MD take_VB place_NN at_IN the_DT Bournemouth_NP International_NP Conference_NP Centre_NP on_IN 2_CD --_: 5_CD July_NP 2003_CD ._SENT BACR_NN =_SYM British_NP Association_NP for_IN Cancer_NP Research_NP ;_: ER_NP =_SYM estrogen_NN receptor_NN ._SENT 